Overall survival of NLPHL and cHL patients treated within the HD16 and HD17 studies. (A) OS of patients with NLPHL (red) and patients with cHL (blue) treated in the HD16 study. (B) OS of patients with NLPHL (red) and patients with cHL (blue) treated in the HD17 study.